CENTRISA LO 28 0.250 MG — DIN 02411458
NORGESTIMATE : 0.250 MG NORGESTIMATE : 0.180 MG ETHINYL ESTRADIOL : 0.025 MG ETHINYL ESTRADIOL : 0.025 MG ETHINYL ESTRADIOL : 0.025 MG NORGESTIMATE : 0.215 MG · PATRIOT A DIVISION OF JANSSEN INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is CENTRISA LO 28?
CENTRISA LO 28 0.250 MG contains NORGESTIMATE : 0.250 MG NORGESTIMATE : 0.180 MG ETHINYL ESTRADIOL : 0.025 MG ETHINYL ESTRADIOL : 0.025 MG ETHINYL ESTRADIOL : 0.025 MG NORGESTIMATE : 0.215 MG. It is listed in the Health Canada Drug Product Database under DIN 02411458, held by PATRIOT A DIVISION OF JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 03-Aug-2017. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CENTRISA LO 28 used for?
Conception control (oral contraception).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Norgestimate And Estrogen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Norgestimate And Estrogen, across 12 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACTAVIS PHARMA COMPANY | 4 | 0 | TRI-LENA 21, TRI-LENA 28, TRI-LENA LO 21, TRI-LENA LO 28 | No marketed DIN |
| JANSSEN INC | 4 | 0 | TRI-CYCLEN LO (21 DAY), TRI-CYCLEN LO (28 DAY), TRI-CYCLEN TABLETS - 21-DAY, TRI-CYCLEN TABLETS - 28-DAY | No marketed DIN |
| PATRIOT A DIVISION OF JANSSEN INC | 4 | 0 | CENTRISA 21, CENTRISA 28, CENTRISA LO 21, CENTRISA LO 28 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.250 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 21-pill and 28-pill DISCREET Packages. |
| Storage | Not explicitly stated in the provided text (standard practice is 15-30°C). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Norgestimate And Estrogen |
|---|---|
| ATC code | G03AB11 |
| AHFS class | 68:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02411458 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2411458 |
| Brand name | CENTRISA LO 28 |
| Generic / active ingredient | NORGESTIMATE : 0.250 MG NORGESTIMATE : 0.180 MG ETHINYL ESTRADIOL : 0.025 MG ETHINYL ESTRADIOL : 0.025 MG ETHINYL ESTRADIOL : 0.025 MG NORGESTIMATE : 0.215 MG |
| Market authorization holder | PATRIOT A DIVISION OF JANSSEN INC |
| Health Canada schedule | Prescription |
| ATC code | G03AB11 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03AB |
| Current status | CANCELLED PRE MARKET |
| Status date | 03-Aug-2017 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
21-day pack: 1 pill daily for 21 days, then 7 days off. 28-day pack: 1 active pill daily for 21 days, then 7 reminder pills daily for 7 days. Take at the same time each day.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Thrombophlebitis, thromboembolic disorders, cerebrovascular/coronary artery disease, liver disease/tumours, breast/estrogen-dependent cancer, undiagnosed vaginal bleeding, pregnancy, hypertension.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular side effects, especially in women over 35. Increased risk of myocardial infarction, thromboembolism, stroke, and hepatic neoplasia.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CENTRISA 21 | 0.215 MG | TABLET | PATRIOT A DIVISION OF JANSSEN INC | CANCELLED PRE MARKET | 02411199 |
| CENTRISA 28 | 0.035 MG | TABLET | PATRIOT A DIVISION OF JANSSEN INC | CANCELLED PRE MARKET | 02411202 |
| CENTRISA LO 21 | 0.025 MG | TABLET | PATRIOT A DIVISION OF JANSSEN INC | CANCELLED PRE MARKET | 02411431 |
| TRI-CYCLEN LO (21 DAY) | 0.215 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 02258560 |
| TRI-CYCLEN LO (28 DAY) | 0.025 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 02258587 |
| TRI-CYCLEN TABLETS - 21-DAY | 0.18 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 02028700 |
| TRI-CYCLEN TABLETS - 28-DAY | 0.035 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 02029421 |
| TRI-LENA 21 | 0.215 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02443597 |
| TRI-LENA 28 | 0.180 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02443600 |
| TRI-LENA LO 21 | 0.025 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02443457 |
2 · Same class — other molecules in ATC G03AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Norgestimate And Ethinylestradiol | TRI-CIRA 21 · TRI-CIRA 28 · TRI-CIRA LO 21 · TRI-CIRA LO 28 · +2 more | 6 | 6 | Yes |
| Norethisterone And Estrogen | LOLO · ORTHO 10/11 TABLETS (21 DAY) · ORTHO 10/11 TABLETS (28 DAY) · ORTHO 7/7/7 TABLETS (21 DAY) · +4 more | 9 | 3 | Yes |
| Levonorgestrel And Estrogen | QUATERNA · SEASONIQUE · TRIPHASIL 21 · TRIPHASIL 21 TAB · +4 more | 8 | 3 | Yes |
| Desogestrel And Estrogen | LINESSA 21 · LINESSA 28 | 2 | 2 | Yes |
| Norgestimate And Estrogen | CENTRISA 21 · CENTRISA 28 · CENTRISA LO 21 · CENTRISA LO 28 · +8 more | 12 | 0 | Not in Canada |
| Progestogens And Estrogens, Sequential Preparations | TRI-PREVIFEM (21 DAY) · TRI-PREVIFEM (28 DAY) | 2 | 0 | Not in Canada |
| Dienogest And Estrogen | NATAZIA | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03AA | Desogestrel And Estrogen · Drospirenone And Estetrol · Drospirenone And Estrogen · Etynodiol And Estrogen · Levonorgestrel And Estrogen · +4 more | 105 | 46 |
| G03AC | Drospirenone · Etonogestrel · Levonorgestrel · Medroxyprogesterone · Norethisterone · +1 more | 13 | 6 |
| G03AD | Levonorgestrel · Ulipristal | 14 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.